LOLOLOL sorry, but that was hilarious. INNV has close to 20 products on the market, some of which generate several mio dollars per year. This is absolutely not a one trick pony as much as you want it to be.
AVEO has ONE product with marketing authorization. Read again: ONE! And it's under close supervision by the EC,ready to be taken off the market in the case of serious adverse events.
The rest is mostly early stage clinical research stuff,nothing an investor should bet on right now.
Being on NASDAQ offers little protection for this kind of binary biotech companies. You know it, we all know it.
Market Data 
Markets 
AI
